Omentin - A new adipokine with many roles to play

Current Issues in Pharmacy and Medical Sciences

Volumn 28, Issue 3, 2015, Pages 176-180

  Halabis, Magdalena ^a   Dziedzic, Marcin ^a   Warchulinska, Joanna ^a   Kaznowska Bystryk, Iwona ^a   Solski, Janusz ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Cardiovascular disease; Diabetes; Inflammation; Metabolic syndrome; Obesity; Omentin

Indexed keywords

ADIPOCYTOKINE; OMENTIN; SEX HORMONE; UNCLASSIFIED DRUG;

ARTICLE; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; END STAGE RENAL DISEASE; ENDOCRINE DISEASE; HUMAN; INFLAMMATION; MALIGNANT NEOPLASTIC DISEASE; METABOLIC SYNDROME X; OBESITY; OVARY POLYCYSTIC DISEASE; PROTEIN BLOOD LEVEL;

EID: 84952789940     PISSN: 2084980X     EISSN: None     Source Type: Journal    
DOI: 10.1515/cipms-2015-0067     Document Type: Article

References (49)

1. Akbarzadeh S., Ghasemi S., Kalantarhormozi M., et al.: Relationship among plasma adipokines, insulin and androgens level, as well as biochemical glycemic and lipidemic markers with incidence of PCOS in woman with normal BMI. Gynecol. Endocrinol., 28, 7, 2012.
2. Alcelik A., Tosun M., Ozlu M. F., et al.: Serum levels of omentin in end-stage renal disease patients. Kidney Blood Press. Res., 35, 6, 2012.
3. Bastard J., Maachi M., Lagathu C. et al.: Recent advances in the relationship between obesity, infammation, and insulin resistance. Eur. Cytokine Netw., 17, 1, 2006.
4. Blüher M.: Adipose Tissue Dysfunction in Obesity. Exp. Clin. Endocrinol. Diabetes, 117, 6, 2009.
5. Bremer A. A., Jialal I.: Adipose tissue dysfunction in nascent metabolic syndrome. J. Obes., ID 393192, 2013. (Epub)
6. Calle E. E., Tun M. J.: Obesity and cancer. Oncogene, 23, 38, 2004.
7. Choi J. H., Rhee E. J., Kim K. H., et al.: Plasma omentin-1 levels are reduced in non-obese woman with normal glucose tolerance and polycystic ovary syndrome. Eur. J. Endocrinol., 165, 5, 2011.
8. Couillard C., Ruel G., Archer W. R., et al.: Circulating levels of oxidative stress markers and endothelial adhesion molecules in men with abdominal obesity. J. Clin. Endocrinol. Metab., 90, 12, 2005.
9. De Pergola G., Silvestris F.: Obesity as a major risk for cancer. J. Obes., 2013:291546, 2013. (Epub)
10. De Souza Batista C. M., Yang R. Z., Lee M. J. et al.: Omentin plasma levels and gene expression are decreased in obesity. Diabetes, 56, 6, 2007.
11. Fazeli M. S., Dashti H., Akbarzadeh S., et al.: Circulating levels of novel adipocytokines in patients with colorectal cancer. Cytokine, 62, 1, 2013.
12. Flehmig G., Scholz M., Klöting N. et al.: Identifcation of Adipokine Clusters Related to Parameters of Fat Mass, Insulin Sensitivity and Infammation. PLoS One, 9, 6, 2014.
13. Hotamisligil G.S.: Infammation and metabolic disorders. Nature, 444 (860-867), 2006.
14. Katsi V., Vamvakou G., Lekakis J., et al.: Omentin, Fat and Heart: Classical Music with New Instruments. Heart, Lung and Circulation, 23, 9, 2014.
15. Klöting N., Fasshauer M., Dietrich A. et al.: Insulin-sensitive obesity. Am. J. Physiol. Endocrinol. Metab., 299, 3, 2010.
16. Lehr S., Hartwig S., Sell H.: Adipokines: a treasure trove for discovery of biomarkers for metabolic disorders. Proteomics Clin. Appl., 6, 1-2, 2012.
17. Liu R., Wang X., Bu P.: Omentin-1 is associated with carotid atherosclerosis in patients with metabolic syndrome. Diabetes Res. Clin. Pract., 93, 1, 2011.
18. Luque-Ramirez M., Martinez-Garcia M. A., Montes-Nieto R., et al.: Sexual dimorphism in adipose tissue function as evidenced by circulating adipokine concentrations in the fasting state and afer an oral glucose challenge. Hum. Reprod., 28, 7, 2013.
19. Mahde A., Shaker M., Al-Mashhadani Z. Study of omentin-1 and other adipokines and hormones in PCOS patient. OMJ, 24, 2, 2009.
20. Moreno-Navarrete J. M., Catalán V., Ortega F. at al.: Circulating omentin concentration increases afer weight loss. Nutr. Metab., 7, 27, 2010.
21. Moreno-Navarrete J. M., Ortega F., Castro A. et al.: Circulating Omentin as a Novel Biomarker of Endothelial Dysfunction. Obesity, 19, 8, 2011.
22. Os̈więcimska J., Suwała A., ͆więtochowska E. et al.: Serum omentin levels in adolescent girls with anorexia nervosa and obesity. Physiol. Res., 2015. (Epub)
23. Otake S., Takeda H., Fujishima S., et al.: Decreased levels of plasma adiponectin associated with increased risk of colorectal cancer. World J. Gastroenterol., 16, 10, 2010.
24. Pan H. Y., Guo L., Li Q.: Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Res. Clin. Pract., 88, 1, 2010.
25. Ridker P. M., Buring J. E., Cook N. R., et al.: C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14719 initially healthy American women. Circulation, 107, 3, 2003.
26. Schäfer A., Neumeier M., Herfarth H., et al.: Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochim. Biophys. Acta, 1732, 1-3, 2005.
27. Schäfer A., Zeitoun M., Wobser H. et al.: Frequency and signifcance of the novel single nucleotide missense polymorphism Val109Asp in humangene encoding omentin in Caucasian patients with type 2 diabetes mellitus or chronic infammatory bowel disease. Cardiovasc. Diabetol., 6, 3, 2007.
28. Senolt L., Polanská M., Filková M. et al.: Vaspin and omentin: new adipokines diferentially regulated at the site of infammation in rheumatoid arthritis. Ann. Rheum. Dis., 69, doi:10.1136/ ard.20 09.119735, 2010.
29. Shetty G. K., Economides P. A., Horton E. S. et al.: Circulating adiponectin and resistin levels in relation to metabolic factors, infammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care, 27, 10, 2004.
30. Tan B. K., Adya R., Farhatullah S. et al.: Omentin-1, a novel adipokine, is decreased in overweight insulin resistant woman with the polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes, 57, 4, 2008.
31. Tan B. K., Adya R., Farhatullah S., et al.: Metformin treatment may increase omentin-1 levels in woman with polycystic ovary syndrome. Diabetes, 59, 12, 2010.
32. Tan B. K., Adya R., Randeva H. S.: Omentin: A Novel Link Between Infammation, Diabesity, and Cardiovascular Disease. TCM, 20, 5, 2010.
33. Tan B. K., Pua S., Syed F., et al.: Decreased plasma omentin-1 levels in Type 1 diabetes mellitus. Diabet. Med., 25, 10, 2008.
34. Tanyasiri P., Celermajer D. S., Adams M. R., et al.: Endothelial dysfunction occurs in peripheral circulation patients with acute and stable coronary artery disease. Am. J. Physiol. Heart Circ. Physiol., 289, 2, 2005.
35. Tönjes A., Fasshauer M., Kratzsch J. et al.: Adipokine Pattern in Subjects with Impaired Fasting Glucose and Impaired Glucose Tolerance in Comparison to Normal Glucose Tolerance and Diabetes. PLoS One, 5, 11, 2010.
36. Uyeturk U., Sarici H., Tekce B. K. et al.: Serum omentin level in patients with prostate cancer. Med. Oncol., 31, 4, 2014.
37. Van Gall L. F., Mertens I. L., de Block C. E.: Mechanisms linking obesity with cardiovascular disease. Nature, 444 (875-880), 2006.
38. Vu A., Sidhom M. S., Bredbeck B. C., et al.: Evaluation of the relationship between circulating omentin-1 concentrations and components of the metabolic syndrome in adults without type 2 diabetes or cardiovascular disease. Diabetology & Metabolic Syndrome, 6, 4, 2014.
39. Wada J.: Vaspin: A novel serpin with insulin-sensitizing efects. Expert Opin. Inv. Drug, 17, 2008.
40. Weisberg S. P., McCann D., Desai M., et al.: Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest., 112, 12, 2003.
41. Xu L., Zhu G. B., Wang L., et al.: Synovial fuid omentin-1 levels are inversely correlated with radiographic severity of knee osteoarthritis. J. Investing Med., 60, 3, 2012.
42. Yamawaki H. Tsubaki N., Mukohda M. et al.: Omentin, a novel adipokine, induces vasodilation in rat isolated blood vessels. Biochem. Biophys. Res. Commun., 393, 4, 2010.
43. Yamawaki H.: Vascular efects of novel adipokines: focus on vascular contractility and infammatory responses. Biol. Pharm. Bull., 34, 3, 2011.
44. Yan P., Liu D., Long M., et al.: Changes of serum omentin levels and relationship between omentin and adiponectin concentrations in type 2 diabetes mellitus. Exp. Clin. Endocrinol. Diabetes, 119, 4, 2011.
45. Yang R. Z., Lee M. J. Hu H. et al.: Identifcation of omentin as a novel depot-specifc adipokine in human adipose tissue: possible role in modulating insulin action. Am. J. Physiol. Endocrinol. Metab., 290, 6, 2006.
46. Zhang Y.Y., Zou L.M.: Omentin-1, new adipokine, promotes apoptosis through regulating Sirt1-dependant p53 deacetylation in hepatocellular carcinoma cells. Eur. J. Pharmacol., 698, 1-3, 2013.
47. Zheng L., Weng M., Qi M., et al.: Aberrant expression of intelectin-1 in gastric cancer: its relationship with clinicopathological features and prognosis. J. Cancer Res. Clin. Oncol., 138, 1, 2012.
48. Zhong X., Li X., Liu F., et al.: Omentin inhibits TNF-α-induced expression of adhesion molecules in endothelial cells via ERK/NK-κB pat hway. Biochem. Biophys. Res. Commun., 425, 2, 2012.
49. Zhong X., Zhang H., Tan H. et al.: Association of serum omentin-1 levels with coronary artery disease. Acta Pharmacologica Sinica, 32, 7, 2011.